Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HK2 | P52789 | 5/20 | 0.50 |
| ▸ | HK1 | P19367 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15943580 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL15491953 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL18770882 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL19687603 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL18778627 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL17082329 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL12015056 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL14613505 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL14154725 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 | |
| SCHEMBL6075407 | 1.00 | PYGB (0.64) | PYGBLMNAKDM4ECYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338333-B1 | Glycopegylation methods and proteins/peptides produced by the methods | RATIOPHARM GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-8853161-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-20140294762-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | NOVO NORDISK A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| US-8076292-B2 | Factor VIII: remodeling and glycoconjugation of factor VIII | NOVO NORDISK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-8063015-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20090093399-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080305991-A1 | Factor IX: remodeling and glycoconjugation of factor IX | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7416858-B2 | Pharmaceutical compositions of glycoconjugates | NEOSE TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7399613-B2 | Sialic acid nucleotide sugars | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080070275-A1 | Factor VIII: Remodeling and glycoconjugation of factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080050772-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-7265085-B2 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265085-B2 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070026485-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | PYGB 3552/4885LMNA 974/4885KDM4E 1129/4885 |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | PYGB 3552/4885LMNA 974/4885KDM4E 1129/4885 |
| US-20070026485-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20170007712-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20070042458-A1 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | EPOR, HBG2, HAMP | PYGB 1958/4885LMNA 2124/4885KDM4E 2288/4885 |
| US-20090093399-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20140294762-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | PYGB 2158/4885LMNA 1603/4885KDM4E 3684/4885 |
| US-20080305991-A1 | Factor IX: remodeling and glycoconjugation of factor IX | F9, F13B, F13A1 | PYGB 2763/4885LMNA 745/4885KDM4E 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.